MNKD - MannKind Corporation
| Previous Close | 1.0700 |
| Open | 1.0500 |
| Bid | 1.0500 x 47300 |
| Ask | 1.1300 x 38500 |
| Day's Range | 1.0400 - 1.0800 |
| 52 Week Range | 0.9400 - 3.0400 |
| Volume | 1,285,417 |
| Avg. Volume | 2,056,252 |
| Market Cap | 200.928M |
| Beta (3Y Monthly) | 2.19 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4450 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- GlobeNewswire•3 days ago
MannKind Repays Maturing Debt Obligation; Buys Back Certain Warrants
WESTLAKE VILLAGE, Calif., July 18, 2019 -- MannKind Corporation (NASDAQ: MNKD) today announced the repayment of outstanding debt by an aggregate amount of approximately $4.0.
- GlobeNewswire•6 days ago
MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients
WESTLAKE VILLAGE, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that it has partnered with GoodRx to help raise awareness on ways patients can save money on their mealtime insulin.
- GlobeNewswire•10 days ago
MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility. This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization.
- Simply Wall St.•12 days ago
What Kind Of Shareholders Own MannKind Corporation (NASDAQ:MNKD)?
If you want to know who really controls MannKind Corporation (NASDAQ:MNKD), then you'll have to look at the makeup of...
- Zacks Small Cap Research•last month
MNKD: ADA Presentations: Positive Pediatric Data Lends Support for Anticipated Pivotal Study. Adult Data Highlights Benefits, Safety of Higher Doses
New data from three different studies of Afrezza was announced at the American Diabetes Association’s 79th Scientific Sessions (June 7 – 11) in San Francisco. This includes safety and PK data from MannKind’s (MNKD) ongoing pediatric study. This pediatric data, which comes from the first of three age-based patient cohorts is particularly insightful as it provides one of the initial meaningful glimpses of utility of Afrezza in younger populations.
- GlobeNewswire•last month
MannKind to Present at the JMP Securities Life Sciences Conference
WESTLAKE VILLAGE, Calif., June 12, 2019 -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for.
- GlobeNewswire•last month
MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions
MannKind Corporation (MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being held June 7-11, in San Francisco, California. MannKind will present a poster with initial information from its ongoing study of Safety and Pharmacokinetics of Technosphere Insulin (Afrezza) in Pediatric Patients ¹ on Monday, June 10. This study is the first step in preparation for a phase 3 safety and efficacy study.
- GlobeNewswire•2 months ago
Afrezza® (insulin human) Inhalation Powder Approved in Brazil
Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, June 03, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) and BIOMM SA (BIOM3.SA) today announced that Afrezza® (insulin human) Inhalation Powder, an ultra rapid-acting mealtime insulin to improve glycemic control in adult patients with diabetes mellitus, has been registered by the Brazilian Health Regulatory Agency (ANVISA).
- Motley Fool•2 months ago
2 Healthcare Stocks That Could Double Your Money
Should you be as excited as the analysts who think these stocks are two-baggers in the making?
- Benzinga•2 months ago
The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
- GlobeNewswire•2 months ago
MannKind Announces Afrezza® Distribution Agreement in Australia
MannKind Corporation (MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. for the commercialization of Afrezza® (insulin human) Inhalation Powder in Australia. "We are excited to partner with AMSL Diabetes to accelerate patients’ access to Afrezza in Australia," said Michael Castagna, Chief Executive Officer of MannKind Corporation.
- Motley Fool•2 months ago
Why MannKind Is Up Big Today
Shares rise after the company receives some praise from a pair of Wall Street analysts.
- Zacks Small Cap Research•2 months ago
MNKD: Product Sales Up 49% on 71% Growth in Demand. Product Margin Continues to Expand
MannKind (MNKD) reported financial results for their first quarter ending March 31st and provided a business update. As it relates to the financials, total revenue was $17.4M, which included $5.1M in product sales and $12.4M in collaboration revenue.
Motley Fool•2 months agoMannKind Corporation (MNKD) Q1 2019 Earnings Call Transcript
MNKD earnings call for the period ending March 31, 2019.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of MNKD earnings conference call or presentation 7-May-19 1:00pm GMT
Q1 2019 MannKind Corp Earnings Call
- Associated Press•2 months ago
MannKind: 1Q Earnings Snapshot
The Westlake Village, California-based company said it had a loss of 8 cents per share. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
MannKind Corporation Reports 2019 First Quarter Financial Results
1Q 2019 Total Revenues of $17.4 million 1Q 2019 Afrezza Net Revenue was $5.1 million; +49% vs. 1Q 2018 1Q 2019 Collaborations and Services Revenue was $12.4 million 1Q 2019 net.
- Zacks•3 months ago
United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.
- GlobeNewswire•3 months ago
MannKind Corporation to Hold 2019 First Quarter Financial Results Conference Call on May 7, 2019
WESTLAKE VILLAGE, Calif., April 30, 2019 -- MannKind Corporation (Nasdaq:MNKD) will release its 2019 first quarter financial results on Tuesday, May 7, 2019 and its management.
- GlobeNewswire•3 months ago
MannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019)
WESTLAKE VILLAGE, Calif., April 25, 2019 -- MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be.
- GlobeNewswire•4 months ago
MannKind to Present at the H.C. Wainwright Global Life Sciences Conference
If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference. Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company. The presentation will be webcast live. To access the webcast, please visit www.hcwevents.com. Interested parties can also access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com. The webcast replay will remain available for 14 days following the live presentation.
- GlobeNewswire•4 months ago
MannKind Receives $12.5 Million Milestone Payment from United Therapeutics
MannKind Corporation (MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil. Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. Pursuant to the agreement, MannKind is eligible to earn additional payments up to $37.5 million upon the achievement of other defined development milestones. MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.
- Market Realist•4 months ago
Analysts Give Positive Recommendations to MannKind in March
How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect upside potential of 75.00% for MannKind (MNKD) based on the company’s closing price on March
- Market Realist•4 months ago
MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Financial performance In the fourth quarter, MannKind Corporation (MNKD) reported revenue of $16.03 million, a YoY (year-over-year) rise of 253.91%. According
Market Realist•4 months agoMNKD or AKBA: Which Is Expected to Report Faster Revenue Growth?
MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Growth trendsIn its fourth-quarter earnings investor presentation, MannKind Corporation (MNKD) announced that Afrezza had seen fiscal 2018 net sales of $17.3
